Common Contracts

First Take

November 8th, 2022

• Filed
  November 8th, 2022

Strategically moving pieces to align novel ophthalmology platform. We highlight that Ocuphire’s announced global license agreement for development and commercialization of its lead small molecule eye drop candidate Nyxol reflects one aspect of several positive strategic moves involving not only Ocuphire, but global healthcare company Viatris Inc. (VTRS; not rated), Famy Life Sciences (private), and Oyster Point Pharma (OYST; Buy; Caufield). At a high level, we note the announcement of Ocuphire’s exclusive development and commercialization license agreement with Famy directly coincides with Viatris’ announced acquisition of both: (1) Famy Life Sciences; and